Armata Pharmaceuticals, Inc. 8-K
PositiveContract / partnership
Additional non-dilutive DoD funding supports AP-SA02 Phase 3 readiness ahead of a planned H2 2026 superiority study in complicated bacteremia.
Filed 2026-06-23 07:10 ET
- 8.01 Other Events
- 9.01 Financial Statements and Exhibits
Summary
Additional U.S. Department of Defense funding for AP-SA02. Armata received $2.5 million in non-dilutive award funding to support Phase 3 readiness of its intravenous treatment candidate for complicated Staphylococcus aureus bacteremia.
Key Figures
- DoD award funding: $2.5M additional; $28.7M total to date. The additional funding is intended to support key Phase 3-readiness activities.
Investor Takeaways
- Armata plans to initiate a Phase 3 superiority study of intravenous AP-SA02 for complicated bacteremia in H2 2026.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3